Description Module
The Description Module contains narrative descriptions of the clinical trial, including a brief summary and detailed description. These descriptions provide important information about the study's purpose, methodology, and key details in language accessible to both researchers and the general public.
Description Module path is as follows:
Study -> Protocol Section -> Description Module
Description Module
Ignite Creation Date:
2025-12-25 @ 3:14 AM
Ignite Modification Date:
2025-12-25 @ 3:14 AM
NCT ID:
NCT05665205
Brief Summary:
The SARS-CoV-2 is a pulmonary pathology which is caused by SARS-COV2 and the main signs and symptoms are fever, dyspnea, cough, fatigue, muscular pain and more. Even if SARS-CoV-2 is an acute respiratory pathology we know that can cause some chronic conditions in the general status health of the patients. Besides, it can have an important impact in the physique condition such as a detrimental of the aerobic capacity, lung capacity based on the severity of the patient.
On the other hand, World Health Organization (WHO) has a criteria to classify the severity of SARS-CoV-2;
Saturation de O2 \<94%,
PaO2/FiO2: \<300mm
Frecuencia respiratoria \> 30p/m
abscess Lung \> 50%
septic shock
Multiorganic failure
Based on the high survival but the important number of side effects of this pathology remaining the detrimental of the health and exercise condition. We justify our study based on an aerobic exercise program with a strength part to improve those conditions of the patients.
Detailed Description:
The investigators develop an aerobic exercise program for two treatment groups which one of them has a strength program as a supplement to verify if the aerobic exercise plus strength improve more than aerobic exercise alone the condition of COVID patients.
The protocol is based on 8 weeks of program with a baseline measurements and a follow ups after the 8ยบ weeks, at 2, 4 and six months after finish the treatment to compare the effectiveness of both treatment and between them.
Study:
NCT05665205
Study Brief:
Protocol Section:
NCT05665205